In a recent filing with the U.S. Securities and Exchange Commission, Endo Health Solutions Inc. reported that it is facing subpoenas by multiple states investigating its pelvic mesh products, including transvaginal mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). Endo is already defending against roughly 22,000 lawsuits in federal multidistrict litigation, state, and Canadian courts that claim its vaginal mesh products are defective and have cause chronic pain, incontinence and permanent deformities. In June Endo agreed to pay $54.4 million to settle an unspecified number of vaginal mesh claims.
[1] U.S. Securities and Exchange Commission Form 10-K, Commission File No. 001-15989, Endo Health Solutions Inc (February 28, 2014).
[1] U.S. Securities and Exchange Commission Form 10-K, Commission File No. 001-15989, Endo Health Solutions Inc (February 28, 2014).
RSS Feed
